Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on BI 706321 PK in Healthy Males
NCT04714073Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bi 706321 in Crohn's disease, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 706321 in Plasma Over the Time Interval From 0 Extrapolated to Infinity and Maximum Measured Concentration of BI 706321 in Plasma. Started Feb 2021; status: completed.
02
Drugs
bi 706321
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04714073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714073.